Neuren Pharmaceuticals (ASX:NEU) said that the US Food and Drug Administration (FDA) granted fast track designation to its drug candidate NNZ-2591 used for the potential treatment of Pitt Hopkins syndrome (PTHS), according to a Tuesday filing with the Australian bourse.
PTHS is a rare neurodevelopmental disorder with no approved treatment, the filing said.
Shares of the company rose past 5% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.